Over the past decade, oncology has entered a period of extraordinary innovation. Advances in checkpoint inhibitors, targeted therapies, antibody-drug conjugates, and cell-based approaches have reshaped treatment paradigms and improved outcomes for many patients. Yet despite this progress, a persistent and fundamental challenge remains: many of the most promising therapies fail to deliver consistent, durable responses across most solid tumors.
The reason is increasingly clear. The bottleneck in oncology is no longer our ability to identify targets or develop potent therapeutic agents. It is our ability to make tumors responsive to those therapies in vivo. At the center of this challenge lies the concept of the ‘cold’ tumor.[1]
Understanding the Cold Tumor Constraint
Immunologically ‘cold’ tumors are characterized by low levels of T-cell infiltration, limited antigen presentation, and an immunosuppressive tumor microenvironment (TME).[1][2] In these settings, even highly effective therapies struggle to generate meaningful clinical responses.
Checkpoint inhibitors, for example, depend on pre-existing immune activity. Without sufficient T-cell presence or tumor antigen visibility, these therapies have little to amplify.[3] Similarly, cell and gene therapies often face barriers in trafficking, persistence, and function within a hostile TME. Even targeted therapies and antibody-drug conjugates – while capable of inducing tumor cell death – may fail to trigger a broader immune-response.
As a result, a significant proportion of patients with solid tumors derive limited benefit from therapies that, in other contexts, can be highly effective. This is not a failure of the therapies themselves. It is a failure of the biological context in which they are deployed.
Why Mechanistic Promise Does Not Translate Clinically
A recurring theme in oncology development is the gap between mechanistic promise and clinical performance. Preclinical models often demonstrate clear anti-tumor activity, yet these results do not consistently translate into desired patient outcomes.
One reason is that many therapeutic strategies have focused on directly killing tumor cells, without sufficiently addressing the underlying immunobiology of the tumor microenvironment. Tumors that evade immune detection or actively suppress immune engagement can persist – even in the presence of potent cytotoxic agents.[3]
In effect, we have developed increasingly sophisticated weapons, but we have not ensured that the immune system is in a position to recognize and respond to the target.
A Shift in Focus: From Killing Tumors to Activating Immunity
To overcome this barrier, the field is undergoing a critical shift – from an emphasis on direct cytotoxicity to a broader focus on immune activation and tumor sensitization. The goal is to convert “cold” tumors into “hot” tumors – those characterized by robust immune infiltration, active antigen presentation, and a pro-inflammatory microenvironment.[4] Achieving this transformation enables the immune system to recognize tumor cells and allows existing therapies, particularly checkpoint inhibitors, to function more effectively.
This has led to increased interest in approaches that can “prime” the tumor microenvironment in situ. These include strategies designed to:
- Enhance antigen release and presentation
- Induce localized immune activation
- Alter tumor metabolism in ways that support immune engagement
- Promote infiltration and activation of effector immune cells
Rather than replacing existing therapies, these approaches aim to unlock their full potential.
The Importance of Sequencing in Combination Therapy
Combination therapy has long been viewed as a solution to overcoming resistance and improving outcomes. However, many combination regimens have produced disappointing results – not because the components lack efficacy, but because they are not deployed in the optimal sequence.
Checkpoint inhibitors, for example, are often introduced before sufficient immune activation has occurred. In such cases, their ability to amplify an immune response is inherently limited. This has led to a growing recognition that sequencing may be as important as combination.[5] An effective treatment paradigm may require:
- Priming the tumor microenvironment to initiate immune recognition
- Expanding the immune response
- Sustaining that response through checkpoint modulation
Without this foundational step of immune activation, even the most advanced therapies may underperform.
An Emerging Inflection Point in Oncology Development
Encouragingly, the industry is beginning to align around this understanding. There is growing interest – both scientifically and commercially – in therapies that can modulate the tumor microenvironment and enhance the activity of existing treatments.
This shift is reflected in recent deal-making trends, where large pharmaceutical companies are increasingly seeking assets that act as “force multipliers” for established immunotherapies. Rather than focusing solely on novel standalone treatments, there is a clear movement toward platforms that can improve response rates across a broad range of tumor types.
In this context, approaches that can demonstrate early evidence of in vivo immune activation are particularly compelling.
Reprogramming the Tumor Microenvironment
A range of emerging strategies is now being explored to address the cold tumor problem. Among them are localized, intratumoral approaches designed to reprogram the tumor microenvironment directly. These approaches seek to create a controlled disruption within the tumor, inducing localized cytotoxic effects while simultaneously releasing tumor antigens and stimulating immune recognition.[6] In doing so, they may help bridge the gap between tumor cell death and systemic immune activation.
Early clinical programs are beginning to provide a useful lens into how this paradigm may evolve. For example, intratumoral enzyme-based approaches designed to modify tumor metabolism and generate localized cytotoxic activity have demonstrated the potential to both debulk tumors and enhance antigen presentation in situ. When paired with checkpoint inhibition, such strategies may help convert immunologically cold tumors into more responsive ones.
One illustrative example is Gedeptin®*, an investigational intratumoral therapy designed to locally activate a prodrug within the tumor microenvironment, generating targeted cytotoxicity while promoting immune recognition. Approaches of this kind are increasingly being evaluated not as standalone therapies, but as foundational components of combination regimens – with the goal of improving response rates and durability across a range of solid tumors.
While still in relatively early stages of clinical validation, these efforts reinforce a broader thesis: effective tumor priming may be a prerequisite for unlocking the full value of immuno-oncology.
Why This Matters Now
The stakes are high. Checkpoint inhibitors and other immunotherapies are already widely used, and billions of dollars have been invested in oncology pipelines. Yet a substantial proportion of patients remain non-responsive. Addressing the cold tumor barrier represents one of the most significant opportunities to improve outcomes – not by replacing existing therapies, but by enabling them to work where they currently fall short.
From a development perspective, therapies that can enhance the effectiveness of established standards of care may also offer more efficient clinical and regulatory pathways, as well as attractive partnership opportunities.
Looking Ahead
The next phase of oncology innovation will likely be defined not by a single breakthrough therapy, but by a more integrated approach to treatment – one that recognizes the central role of the tumor microenvironment. Winning strategies will be those that:
- Demonstrate clear mechanistic impact within the TME
- Integrate effectively with existing therapies
- Employ thoughtful sequencing to maximize response
- Show early and convincing in vivo evidence of immune activation
Ultimately, the goal is not just to destroy cancer cells, but to enable the immune system to recognize and eliminate them.
Conclusion
The challenge of cold tumors has exposed a critical limitation in our current approach to cancer therapy. It has also illuminated a path forward. By focusing on tumor priming and immune activation, the field has an opportunity to unlock the full potential of the therapies already at our disposal. In doing so, we may finally begin to close the gap between scientific promise and clinical reality – and deliver more consistent, durable outcomes for patients.
__
Clinical trials
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer – ClinicalTrials.gov ID NCT03754933
References
[1] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017 Jan 18;541(7637):321-330. doi: 10.1038/nature21349. PMID: 28102259. DOI:
[2] Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. PMID: 29686425; PMCID: PMC5998822.
[3] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017. PMID: 28187290; PMCID: PMC5391692.
[4] Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019 Mar;18(3):197-218. doi: 10.1038/s41573-018-0007-y. PMID: 30610226.
[5] Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020 Jan 14;52(1):17-35. doi: 10.1016/j.immuni.2019.12.011. PMID: 31940268.
[6] Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017 Dec 1;28(suppl_12):xii33-xii43. doi: 10.1093/annonc/mdx683. PMID: 29253115.
Featured image: Canet de Mar, Spain; Photo courtesy: © 2018 – 2026 Unsplash License. Used with permission.
DOI
